Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

Table 2 Summary of clinical trials targeting MDSCs in hematological malignancy

NCT number	Drug name	Target	Indications	Last reported status	Phase
NCT01393106	Idelalisib	PI3K	Hodgkin lymphoma	Completed	II
NCT01374217	Tadalafil, Lenalidomide, Dexamethasone	PDE5	MM	Recruiting	II
NCT02916979	Fludarabine, Busulfan	/	Leukemia, MDS	Active, not recruiting	I
NCT03480360	Cyclophosphamide, Fludarabine	/	Leukemia	Recruiting	III
NCT01563302	IONIS-STAT3Rx	STAT3	DLBCL lymphoma	Completed	I/II
NCT03214666	GTB-3550 TriKE™	CD33	Leukemia	Recruiting	I/II
NCT02076451	DS-8273a	TRAIL-R2	Lymphoma	Completed	I
NCT04405167	Tasquinimod, IRd chemotherapy	S100A9	MM	Recruiting	I
NCT04915248	Daratumumab, Bortezomib, Dexamethasone	CD38	Plasmablastic Lymphoma	Recruiting	II
NCT02846376	Nivolumab, Ipilimumab	CTLA-4, PD-1	AML, MDS	Active, not recruiting	I
NCT04147533	Dasatinib, Nilotinib	BCR-ABL	CML	Recruiting	II
NCT05032820	Lenalidomide, bb2121	/	MM	Recruiting	II
NCT01675141	Lenalidomide	/	MM	Completed	II
NCT05293912	SG2501	CD38	Hematological Malignancy	Recruiting	I
NCT02936752	Entinostat	HDAC	MDS	Active, not recruiting	I
NCT02922764	RGX-104, Nivolumab, Ipilimumab	LXR	advanced solid tumors, lymphoma	Recruiting	I
NCT01347996	histamine dihydrochloride, IL-2	NOX2	AML	Completed	IV
NCT03144245	AMV564	CD33	AML	Completed	I
NCT03516591	AMV564	CD33	MDS	Completed	I

ISSN: 2050-7771